title: Potential drug-drug interactions in hospitalised haematological patients.
abstract: Background Frequently, haematological patients undergo highly complex and intensive treatment protocols, so a high risk of drug-drug interactions could be expected. Objectives To determine prevalence of clinically relevant drug-drug interactions, to identify the most frequent drug-drug interactions and associated risk factors. Methods A prospective, observational and descriptive study was carried out from November 2012 to February 2013. Twice a week, every patient's treatment sheet was collected. Each medication list was screened through two databases: Thomson MicromedexTM and Drug Interaction FactsTM. All identified potential drug-drug interactions with a moderate or higher severity rating were recorded. Summary statistics were used to describe patient and disease characteristics, most often prescribed drugs, and frequency, types and classification of drug-drug interactions. Multiple logistic regression models were used to identify risk factors associated with drug-drug interactions. Results A total of 2061 drug-drug interactions were detected in 317 treatment sheets from 58 patients. The prevalence of treatment sheets with drug-drug interactions by Micromedex and Drug Interaction Facts databases were 74.1% and 56.8%, respectively. Azole antifungals, immunosuppressive drugs, antiemetics, antidepressants, acid suppressants and corticosteroids were the most frequent involved drugs. In multivariate analysis, the main risk factor associated with increased odds for drug-drug interactions was a higher number of non-antineoplastic drugs. Conclusions The prevalence of drug-drug interactions was common, with immunosuppressant and azole antifungal agents being the most commonly involved drugs. The factor having the greatest influence on drug-drug interactions was a higher number of non-antineoplastic drugs.
authors: 1 Pharmacy Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.
authors: Ma Ángeles
authors: MÁ
authors: Fernández de Palencia Espinosa
authors: 1 Pharmacy Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.
authors: Ma Sacramento
authors: MS
authors: Díaz Carrasco
authors: 2 Haematology Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.
authors: Andrés
authors: A
authors: Sánchez Salinas
authors: 1 Pharmacy Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.
authors: Amelia
authors: A
authors: de la Rubia Nieto
authors: 3 Pharmacology Department, University of Murcia, Murcia, Spain.
authors: Alberto Espuny
authors: AE
authors: Miró
mesh_terms: D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D016208:Databases, Factual; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D007166:Immunosuppressive Agents
keywords: Drug–drug interaction; chemotherapy; haematological; inpatient